A Brief Clinical Update on Hepatitis C--The Essentials

Area of Science:

• Hepatology
• Infectious Diseases
• Public Health

Background:

• Hepatitis C virus (HCV) infection is a leading cause of cirrhosis, liver failure, and liver transplantation in the U.S.
• An estimated 74,000 individuals in Wisconsin have HCV, with a significant portion undiagnosed.
• HCV incidence is rising in Wisconsin, linked to increased intravenous heroin use.

Purpose of the Study:

• To review current guidelines for screening, diagnosis, and treatment of HCV infections.
• To highlight advancements in HCV treatment with direct-acting antiviral medications.
• To address challenges in HCV management, including medication cost and accessibility.

Main Methods:

• Literature review of current HCV screening, diagnosis, and treatment guidelines.
• Analysis of HCV prevalence and incidence trends in Wisconsin.
• Discussion of novel direct-acting antiviral therapies and their clinical impact.

Main Results:

• Direct-acting antiviral medications have transformed HCV treatment, yielding high cure rates.
• Significant numbers of HCV infections remain undiagnosed in Wisconsin.
• Rising HCV rates correlate with increased intravenous drug use in the state.

Conclusions:

• Effective screening and diagnosis are crucial for managing the HCV epidemic in Wisconsin.
• While new treatments are highly effective, high costs and limited availability pose significant barriers to widespread care.
• Addressing the interplay of substance use and HCV transmission is essential for public health efforts.